Search | Clinical Trials Finder

Conditions: Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions: tafasitamab, parsaclisib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 6 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: MDX-1342; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Boston, Massachusetts • Buffalo, New York • Houston, Texas

Conditions: Idiopathic Membranous Nephropathy
Interventions: Rituximab, Cyclosporine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more

Conditions: Non Hodgkin's Lymphoma Refractory/Relapsed
Interventions: N803, CD19t-haNK suspension, Cyclophosphamide, Fludarabine, Rituximab; Drug · Biological
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Newport Beach, California • Tyler, Texas

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions: Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin; Procedure · Drug · Biological + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pemphigus
Interventions: Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)
Interventions: Blinatumomab, Cytarabine, Methotrexate, Ponatinib; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Ibrutinib, Lisocabtagene Maraleucel, Nivolumab, Pheresis, Positron Emission Tomography; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Duarte, California • New York, New York

Conditions: Relapsed or Refractory Large B-cell Lymphoma
Interventions: Loncastuximab Tesirine, Rituximab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Salt Lake City, Utah

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Rituximab, Bendamustine, MEDI-551; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 14
States / cities: Birmingham, Alabama • Burbank, California • La Jolla, California + 11 more

Conditions: B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
Interventions: IKS03; Drug
Lead sponsor: Iksuda Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Glioblastoma, Refractory Glioblastoma
Interventions: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Ipilimumab, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 14 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: Fludarabine Phosphate, Mesna, Cyclophosphamide, Total nodal irradiation, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Mycophenolate Mofetil, Tacrolimus, Rituximab; Drug · Radiation · Biological + 1 more
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tafasitamab, Tafasitamab plus lenalidomide; Drug
Lead sponsor: MorphoSys AG; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Tucson, Arizona • Anaheim, California • Duarte, California + 20 more

Conditions: Lymphoma
Interventions: milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab; Biological · Procedure
Lead sponsor: Beth Christian; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Tafasitamab, Zanubrutinib; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Duarte, California • Irvine, California • Miami, Florida

Conditions: Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegfilgrastim, Rituximab, Vincristine Sulfate; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate; Procedure · Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 207
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more

Conditions: Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions: Rituximab, Tafasitamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Survey Administration; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 365 Days
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 115
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Leukemia, Acute Lymphoblastic, Small Lymphocytic Lymphoma
Interventions: Autologous HuCD19 ( Anti-CD19)CAR T cells, Cyclophosphamide, Fludarabine, Rituximab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions: Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions: ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide; Genetic · Biological · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 24
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more

Search by objective public record fields.

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

MEmbranous Nephropathy Trial Of Rituximab

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)